Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2000-02-10
2008-07-08
Allen, Marianne P. (Department: 1647)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C514S012200, C530S399000, C435S366000, C435S375000
Reexamination Certificate
active
07396809
ABSTRACT:
The invention relates to methods for potentiating, enhancing or restoring glucose responsivity in pancreatic islets or cells. The methods can be used as therapies for diseases caused by, or coincident with, aberrant glucose metabolism, such as Type II Diabetes Mellitus.
REFERENCES:
patent: 4683195 (1987-07-01), Mullis et al.
patent: 4683202 (1987-07-01), Mullis
patent: 4839343 (1989-06-01), Waeber et al.
patent: 4891357 (1990-01-01), Kalra
patent: 4892538 (1990-01-01), Aebischer et al.
patent: 5459039 (1995-10-01), Modrich et al.
patent: 5498531 (1996-03-01), Jarrell
patent: 5574010 (1996-11-01), McFadden
patent: 5604203 (1997-02-01), Balasubramaniam
patent: 5696093 (1997-12-01), Tseng et al.
patent: 5912227 (1999-06-01), Croom et al.
patent: 5939462 (1999-08-01), Connell et al.
patent: 5968819 (1999-10-01), Gerald et al.
patent: 5980945 (1999-11-01), Ruiz
patent: 6013622 (2000-01-01), Bruno et al.
patent: 6391343 (2002-05-01), Yen
patent: 6558708 (2003-05-01), Lin
patent: 6569832 (2003-05-01), Knudsen et al.
patent: 2002/0094346 (2002-07-01), Lin
patent: 2003/0224983 (2003-12-01), Nielsen
patent: 2004/0228846 (2004-11-01), Pang et al.
patent: 0 992 239 (2003-03-01), None
patent: WO 89/01967 (1989-03-01), None
patent: WO 90/02580 (1990-03-01), None
patent: WO 90/15637 (1990-12-01), None
patent: WO 91/10425 (1991-07-01), None
patent: WO 91/10470 (1991-07-01), None
patent: WO 94/16101 (1994-07-01), None
patent: WO-99/15516 (1999-04-01), None
patent: WO-00/47219 (2000-08-01), None
patent: WO-00/68197 (2000-11-01), None
patent: WO-01/62737 (2001-08-01), None
patent: WO-01/76631 (2001-10-01), None
patent: WO-03/026591 (2003-04-01), None
Freshney, I. R. Culture of Animal Cells, A Manual of Basic Technique. (Alan R. Liss, Inc. 1983, New York, NY).
Dox, I.G. et al. The Harper Collins Illustrated Medical Dictionary. (HarperCollins Publishers, Inc. 1993 New York, NY).
Wells, JA Additivity of Mutational Effects in Proteins. Biochemistry 29:8509-8517 (1990).
Nog et al. Computational Complexity, Protein Structure Prediction and the Levinthal Paradox. The Protein Folding Problem and Tertiary Structure Prediction. 492-495 Birkhauser Boston (1994).
Well, JA Additivity of Mutational Effects in Proteins. Biochemistry 29:8509-8517 (1990).
Freshney; Culture of Animal Cells, A Manual of Basic Technique, Alan R. Liss, Inc., New York, p4 (1983).
On-Line Medical Dictionary. Dept. of Oncology, University of Newcastle upon Tyne. The CancerWeb Project Copyright 1997-2004.
Morley et al., An investigation of tolerance to the actions of leptogenic and anorexigenic drugs in mice. Life Sciences, vol. 41, p. 2157-2165 (1987).
Aponte et al.; “Meal-Induced Peptide Tyrosine Tyrosine Inhibition of Pancreatic Secretion in the Rat”, The FASEB Journal, 3: 1949-1955 (Jun. 1989).
Ahrén , B. and Larsson, H. “Peptide YY Does not Inhibit Glucose-Stimulated Insulin Secretion in Humans”, European Journal of Endocrinology 134: 362-365, (1996).
Barany Francis; “Genetic Disease Dtection and DNA Amplification Using Cloned Thermostable Ligase”, Proc. Natl. Acad. Sci. USA, 88: 189-193, (Jan. 1991).
Berge et al.; “Pharmaceutical Salts”, Journal of Pharmaceutical Sciences, 66(1): 1-19 (Jan. 1977).
Birdsall and Hulme; “Muscarinic Receptor Subclasses”, TIPS, pp. 459-463, (1983), Nov.
Braesch et al.; “Immune Response of Diabetic Patients Against Transplanted Porcine Fetal Islet Cells”, Transplantation Proceedings 24(2): 679-680, (Apr. 1992).
Cook and Hales; “Intracellular ATP Directly Blocks K+Channels in Pancreatic B-Cells”, Nature, 311: 271-273, (Sep. 20, 1984).
Coruzzi et al.; “Gastric Antisecretory Activity of Telenzepine, a New M1—Selective Muscarinic Antagonist: Comparison with Pirenzepine”, Arch. Int. Pharmacodyn. 302: 232-241 (1989).
Cotton, R.G. H.; “Current Methods of Mutation Detection”, Mutation Research, 285: 125-144, (1993).
Cotton et al.; “Reactivity of Cytosine and Thymine in Single- Base -pair Mismatches with Hydroxylamine and Osmium Tetroxide and its Application to the Study of Mutations”, Proc. Natl. Acad. Sci. USA 85: 4397-4401 (Jun. 1988).
Cox and Cuthbert; “The Effects of Neuropeptide Y and its Fragments upon Basal and Electrically Stimulated Ion Secretion in Rat Jejunum Mucosa,”, Br. J. Pharmacol. 101:247-252 (1990).
Dea et al.; “Molecular Heterogeneity of Human Motilinlike Immunoreactivity Explained by the Processing of Prepromotilin”, Gastroenterology 96: 695-703, (1989).
Ferber et al.; “GLUT-2 Gene Transfer into Insulinoma Cells Confers Both Low and High Affinity Glucose-Stimulated Insulin Release”, The Journal of Biological Chemistry, 269(15): 11523-11529 (1994).
Gehlert R. D.; “Multiple Receptors for the Pancreatic Polypeptide (PP-Fold) Family: Physiological Implications (44263)”, P.S.E.B.M. , 218: 7-22 (1998).
Gibbs et al.; “Detection of Single DNA base Differences by Competitive Oligonucleotide Priming”, Nucleic Acids Research , 17(7): 2437-2448, (1989).
Groth et al.; “Evidence of Xenograft Function in a Diabetic Patient Grafted with Porcine Fetal Pancreas”, Transplantation Proceedings, 24(3): 972-973, (Jun. 1992).
Gold et al.; “Effect of Age on Proinsulin and Insulin Secretory Patterns in Isolated Rat Islets”, Diabetes, 30: 77-82, (Jan. 1981).
Greeley et al.; “Peptide YY Antagonizes β-adrenergic-stimulated release of Insulin in Dogs”, Am. J. Physiol. 254: E513-E517 (1988).
Holiday and Cox; “The Functional Investigation of a Human Adenocarcimona Cell Line, Stably Transfected with the Neuropeptide YY1Receptor”, British Journal of Pharmacology 119: 321-329, (1996).
Hsu et al.; “Detection of DNA Point Mutations With DNA Mismatch Repair Enzymes”, Carcinogenesis 15(8): 1657-1662 (1994).
Hughes et al.; “Engineering of Glucose-Stimulated Insulin Secretion and Biosynthesis in Non-Islet Cells”, Proc. Natl. Acad. Sci. USA, 89: 688-692 (Jan. 1992).
Jackerott et al.; “PYY in Developing Murine Islet Cells: Comparisons to Development of Islet Hormones, NPY, and BrdU Incorporation1”, The Journal of Histochemistry and Cytochemistry, 44 (8): 809-817 (1996).
Jackerott and Larsson; “Immunocytochemical Localization of the NPY/PYY Y1 Receptor in the Developing Pancreas”, Endocrinology 138(11): 5013-5018 (1997).
Johnson et al.; “Underexpression of η Cell High KmGlucose Transporters in Noninsulin-Dependent Diabetes”, Science, 250: 546-549 (Oct. 26, 1990).
Jones: “Protein Kinases, Protein Phosphorylation, and the Regulation of Insulin Secretion from Pancreatic β-Cells.” Endocrine Reviews 19(4): 429-416 (Aug. 1998).
Korsgren et al.; “Large -Scale Production of Fetal Porcine Pancreatic Isletlike Cell Clusters”, Transplantation, 45: 509-514 (Mar. 1998).
Krasinski et al.; “Isolation, Characterization, and Development Expression of the Rat Peptide-YY Gene”, Mol. Endo. 5(3): 433-440, (1991).
Lacy et al.; “Maintenance of Normoglycemia in Diabetic Mice by Subcutaneous Xenografts of Encapsulated Islets”, Science 254: 1782-1784 (Dec. 20, 1991).
Landegren et al.; “A Ligase-Mediated Gene Detection Technique”, Science, 241: 1077-1080 (Aug. 26, 1988).
Lui et al.; “Persistent Reversal of Diabetes by Transplantation of Fetal Pig Proislets Into Nude Mice”, Diabetes 40: 858-866, (Jul. 1991).
Lluis et al.; “Peptide YY Inhibits Pancreatic Secretion by Inhibiting Cholecystokinin Release in the Dog”, Gastroenterology, 94: 137-144, (1988)
Lundberg et al.; “Localization of Peptide YY (PYY) in Gastrointestinal Endocrine Cells and Effects on Intestinal Blood Flow and Motility”, Proc. Natl. Acad. Sci. USA 79: 4471-4475, (Jul. 1982).
Maxam and Gilbert; “A New Method for Sequencing DNA”, Proc. Natl. Acad. Sci. USA, 74(2): 560-564 (Feb. 1977).
Mulder et al.; “Express
Lu Kuanghui
Pang Kevin
Allen Marianne P.
Curis, Inc.
Deberry Regina M
Ropes & Gray LLP
LandOfFree
Methods and reagents for treating glucose metabolic disorders does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods and reagents for treating glucose metabolic disorders, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods and reagents for treating glucose metabolic disorders will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3968085